Literature DB >> 9433335

Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic.

M Maj1, R Pirozzi, L Magliano, L Bartoli.   

Abstract

OBJECTIVE: In this prospective study, information was collected on all bipolar I patients who started lithium prophylaxis at a lithium clinic during more than 15 years.
METHOD: Patients were evaluated bimonthly with standardized instruments for as long as they took lithium. Treatment surveillance conformed to internationally accepted guidelines. Five years after starting prophylaxis, each patient was contacted for a follow-up interview.
RESULTS: Of the 402 enrolled patients, 27.9% were no longer taking lithium at follow-up; 38.1% were taking lithium and had had at least one recurrence of the disorder; and 23.4% were taking lithium and had had no recurrence. Among patients still taking lithium whose plasma lithium levels had been below 0.5 mmol/liter on no more than 10% of checks, 88.0% had at least a 50% reduction in mean annual time spent in the hospital compared to a reference pretreatment period, and 43.0% had had no recurrence. Patients not taking lithium at follow-up had a poorer outcome than those taking lithium, but patients no longer taking any psychotropic drug did not differ from those taking lithium. Patients no longer taking lithium had had a higher frequency of psychotic features in the index episode than those still taking lithium.
CONCLUSIONS: The impact of lithium prophylaxis on the course of bipolar disorder is severely limited by the high dropout rate. In bipolar patients taking lithium regularly for several years, a drastic reduction of time spent in the hospital is almost the rule; these patients represent a self-selected population in which at least one group at high risk of poor outcome is under-represented.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9433335     DOI: 10.1176/ajp.155.1.30

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  30 in total

Review 1.  Polytherapy in bipolar disorder.

Authors:  Daniel Lin; Hiram Mok; Lakshmi N Yatham
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Easing the burden of bipolar disorder: from urgent situations to remission.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  Who are excellent lithium responders and why do they matter?

Authors:  Martin Alda
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

4.  The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998.

Authors:  C E Begley; J F Annegers; A C Swann; C Lewis; S Coan; W B Schnapp; L Bryant-Comstock
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder.

Authors:  William V Bobo; Richard A Epstein; Alan Lynch; Tynya D Patton; Nicholas A Bossaller; Richard C Shelton
Journal:  Clin Neuropharmacol       Date:  2011 Nov-Dec       Impact factor: 1.592

6.  Rapid cycling bipolar disorders in primary and tertiary care treated patients.

Authors:  Tomas Hajek; Margaret Hahn; Claire Slaney; Julie Garnham; Joshua Green; Martina Růzicková; Peter Zvolský; Martin Alda
Journal:  Bipolar Disord       Date:  2008-06       Impact factor: 6.744

7.  Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment.

Authors:  A Perry; N Tarrier; R Morriss; E McCarthy; K Limb
Journal:  BMJ       Date:  1999-01-16

Review 8.  Women and bipolar disorder across the life span.

Authors:  Dorothy Sit
Journal:  J Am Med Womens Assoc (1972)       Date:  2004

9.  Oxcarbazepine versus Divalproex Sodium for the Continuing Treatment of Mania.

Authors:  Michael J Reinstein; John G Sonnenberg; Thomas G Hedberg; Lynne E Jones; Polina Reyngold
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 10.  The behavioral actions of lithium in rodent models: leads to develop novel therapeutics.

Authors:  Kelley C O'Donnell; Todd D Gould
Journal:  Neurosci Biobehav Rev       Date:  2007-04-13       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.